U.S. Orders More Monkeypox Vaccines from Bavarian Nordic
July 01 2022 - 10:11AM
Dow Jones News
By Dean Seal
Bavarian Nordic A/S said Friday that the U.S. Department of
Health and Human Services has ordered an additional 2.5 million
doses of the liquid-frozen form of its monkeypox vaccine.
The Denmark-based company said deliveries of its vaccine, known
as Jynneos in the U.S., under this contract will start in the
fourth quarter of 2022 and continue through early next year.
The U.S. Biomedical Advanced Research and Development Authority,
a branch of the Health and Human Services Department, already
ordered half a million doses of the vaccine a few weeks ago in
response to reports of a monkeypox outbreak.
Combined with the government's previous order for 1.4 million
doses in 2020, a total of 4.4 million doses will be delivered in
2022 and 2023, Bavarian Nordic said.
Jynneos is the only vaccine that currently has regulatory
approval in the U.S. for use against monkeypox.
The doses sent to the U.S. will be made from already
manufactured bulk vaccine, which also will be used to make a
freeze-dried version of Jynneos pending approval from the U.S. Food
and Drug Administration.
U.S. health officials said this week that they would expand
their efforts to curb the spread of monkeypox, a viral disease that
has been confirmed in more than 300 people around the country. The
Centers for Disease Control and Prevention recommends vaccines for
people with presumed exposure to monkeypox, and not just confirmed
exposure.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 01, 2022 10:56 ET (14:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.